Leveraging Mobile Health Technology to Optimize Early Stimulant Medication Treatment: A Feasibility Pilot

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

26 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2018-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to develop and test a mobile web application to optimize early stimulant medication treatment for children receiving care for Attention/Deficit Hyperactivity Disorder (ADHD) in a publicly-funded mental health clinic.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Text Messaging Adherence to Stimulant Medication

NCT01967485

Attention Deficit Hyperactivity Disorder

COMPLETED NA

Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children

NCT00183391

Attention Deficit Disorder With Hyperactivity

COMPLETED PHASE4

A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

NCT00922636

Attention Deficit Hyperactivity Disorder

COMPLETED PHASE2/PHASE3

Methylphenidate for Treating Children With ADHD and Tourette Syndrome

NCT00441649

Attention Deficit Disorder With Hyperactivity Tourette Syndrome

COMPLETED NA

Improving Attention Deficit Hyperactivity Disorder Treatment Adherence and Outcome in Primary Care Settings

NCT00179894

Attention Deficit Disorder With Hyperactivity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In other words, the study will find out whether it is feasible and acceptable for parents to receive reminders for clinic visits and ADHD medication and enter daily ratings of their child's ADHD symptoms and medication side effects into a smart phone. It will also examine whether it is feasible and acceptable for doctors to use this information summarized on a tablet (iPad) screen during a medication follow-up visit. If the parent consents, the study will also examine whether it is feasible and acceptable for the child's teacher to enter their ratings of ADHD symptoms twice a week using a link on their email. This information will also be included in the doctor's iPad screen. If this technology is found to be promising, then a larger study will be done to examine if medication treatment is safer, more consistent, and more effective using this technology compared to usual care. This is important because the technology may remove the burden on parents and teachers to report ADHD symptoms and medication side effects using paper forms, and for doctors to record this information in the medical record. In total, there will be 12 parent/ child dyads, 6 clinicians and up to 12 teachers enrolled. Each parent/child dyad will be videotaped for up to 3 visits with the clinician (n=36 videotaped sessions). The study time period is from the first visit that ADHD medication is prescribed to the time of the third follow-up medication visit. We anticipate that the follow-up visits will be every 1-2 weeks during this early phase of stimulant medication treatment. Thus, the study time period for each parent/child dyad will be between 4-8 weeks. We anticipate that data collection will occur between August 19, 2013 and June 31, 2014.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Attention Deficit Disorder With Hyperactivity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* parent's and child's primary language is English or Spanish
* child is between 5-11 years
* child received a clinical diagnosis of ADHD
* child is receiving stimulant medication for the first time
* child does not take any other medication on a regular basis (like every day)

Exclusion Criteria

* any chronic medical condition that requires on-going medication management
* prescription of combined psychotropic medication
* moderate-severe developmental delays, mental retardation or autism

Minimum Eligible Age

5 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bonnie Zima, MD MPH

Associate Director of the Jane and Terry Semel Institute's Health Services Research Center and Professor-in-Residence in the UCLA Department of Psychiatry and Behavioral Sciences at the David Geffen School of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR